Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this observational study is to compare what drugs work best in sedating children (> 3 months to < 36 months) who need an MRI. This type of research may help clinicians (healthcare providers) learn more about how dexmedetomidine works compared to propofol. The investigators are planning to have 60 children complete the study at Children's Healthcare of Atlanta at Scottish Rite. Half (30) of the patients will be randomized to receive dexmedetomidine and the other half will receive propofol. (Both drugs are licensed and approved for the sedation performed for consented patients.)


Clinical Trial Description

There are several different medications commonly being used to facilitate the administration of radiologic procedures on children. Procedures such as Magnetic Resonance Imaging (MRIs) require that the patient remain still for the duration of the test. Propofol has become the drug of choice for many sedation services due to its rapid onset of action, rapid recovery time, ability to achieve sedation reliably and favorable safety profile. Dexmedetomidine, a selective alpha-2- adrenergic agonist, has also gained popularity with sedation services. Its main advantage over propofol is that it has minimal respiratory complications when compared to propofol. The sedative effect from dexmedetomidine preserves a natural sleep pattern and induces cooperative sedation in which patients are easily arousable. In pediatric studies, the most frequent adverse effect have been related to its potential to cause hypotension and bradycardia, which resolve with dose reduction. Additionally, dexmedetomidine does not seem to have as much impairment of cognitive function and has an opioid sparing effect. Dexmedetomidine, however, has a longer onset of action and longer recovery time compared to propofol, which has limited its use with many sedation services. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03552146
Study type Observational
Source Children's Healthcare of Atlanta
Contact David Fagin, MD
Phone 404-785-6000
Email david.fagin@pema.com
Status Recruiting
Phase
Start date July 24, 2018
Completion date September 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT03420898 - Reducing Sedatives in Hospital Study
Completed NCT04866433 - The Effect of Real-time Binaural Sound on Sedation Using Dexmedetomidine N/A
Active, not recruiting NCT03698487 - Pharmacist Led Intervention to Improve Medication Use in Older In-patients Living With Frailty: the Drug Burden Index N/A
Recruiting NCT03392012 - Effect of Sedation on Pulmonary Aeration in Children N/A
Recruiting NCT06225037 - EEG-guided Propofol Sedation Versus Standard Care for Oesophagogastroduodenoscopy and Colonoscopy in Children N/A
Completed NCT03995134 - Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry
Completed NCT04226443 - The Use of Midazolam and Remifentanil During Dialysis Access Procedures N/A
Completed NCT05451381 - Vasopressor Requirements Depends on Sedation Strategy N/A